Q3676533 (Q3676533): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: importing one item from France) |
(Created claim: summary (P836): The Genialis project “Development of surfactant-free emulsions for the manufacture of sterile injectable emulsions” aims to develop a new emulsion to treat dry eye without surfactants containing toxic substances that can cause side effects. To achieve this result, the following steps must be carried out: —Develop a prototype to control formed particles that meet pharmaceutical requirements -Produce emulsions without an active ingredient, sterili...) |
||||||||||||||
| Property / summary | |||||||||||||||
The Genialis project “Development of surfactant-free emulsions for the manufacture of sterile injectable emulsions” aims to develop a new emulsion to treat dry eye without surfactants containing toxic substances that can cause side effects. To achieve this result, the following steps must be carried out: —Develop a prototype to control formed particles that meet pharmaceutical requirements -Produce emulsions without an active ingredient, sterilise them and test their effectiveness -Develop partnerships with pharmaceutical manufacturers potentially and ultimately commercialise this new product. (English) | |||||||||||||||
| Property / summary: The Genialis project “Development of surfactant-free emulsions for the manufacture of sterile injectable emulsions” aims to develop a new emulsion to treat dry eye without surfactants containing toxic substances that can cause side effects. To achieve this result, the following steps must be carried out: —Develop a prototype to control formed particles that meet pharmaceutical requirements -Produce emulsions without an active ingredient, sterilise them and test their effectiveness -Develop partnerships with pharmaceutical manufacturers potentially and ultimately commercialise this new product. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The Genialis project “Development of surfactant-free emulsions for the manufacture of sterile injectable emulsions” aims to develop a new emulsion to treat dry eye without surfactants containing toxic substances that can cause side effects. To achieve this result, the following steps must be carried out: —Develop a prototype to control formed particles that meet pharmaceutical requirements -Produce emulsions without an active ingredient, sterilise them and test their effectiveness -Develop partnerships with pharmaceutical manufacturers potentially and ultimately commercialise this new product. (English) / qualifier | |||||||||||||||
point in time: 18 November 2021
| |||||||||||||||
Revision as of 11:15, 18 November 2021
Project Q3676533 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3676533 in France |
Statements
400,000.0 Euro
0 references
1,020,955.39 Euro
0 references
39.18 percent
0 references
1 September 2016
0 references
31 August 2020
0 references
GENIALIS
0 references
Le projet de « Développement d’émulsions sans tensio-actif pour la fabrication d’émulsions stériles injectables » porté par la société GENIALIS a pour objectif le développement d’une nouvelle émulsion pour traiter la sécheresse oculaire sans tensioactifs contenant des toxiques pouvant entrainer des effets secondaires. Pour parvenir à ce résultat, les étapes suivantes doivent être réalisées : -Concevoir un prototype permettant de contrôler les particules formées et répondant aux exigences pharmaceutiques -Produire des émulsions sans principe actif, les stériliser et tester leur efficacité -Développer des partenariats avec des industriels pharmaceutiques permettant potentiellement et, à terme, la commercialisation de ce nouveau produit. (French)
0 references
The Genialis project “Development of surfactant-free emulsions for the manufacture of sterile injectable emulsions” aims to develop a new emulsion to treat dry eye without surfactants containing toxic substances that can cause side effects. To achieve this result, the following steps must be carried out: —Develop a prototype to control formed particles that meet pharmaceutical requirements -Produce emulsions without an active ingredient, sterilise them and test their effectiveness -Develop partnerships with pharmaceutical manufacturers potentially and ultimately commercialise this new product. (English)
18 November 2021
0 references
Identifiers
CT0006611
0 references